Cost- effectiveness analysis of nevirapine vs. Ritonavir-boosted lopinavir in hiv-infected children with peripartum nevirapine exposure, in resource-constrained areas from a payer’s perspective
Abstract
Authors
O. Godwin E.B. Ettienne L.M. Brown